Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 50 articles:
HTML format



Single Articles


    January 2025
  1. BASHIR BA
    Chronic Myeloid Leukemia with Hyperleukocytosis.
    N Engl J Med. 2025;392:72.
    PubMed    


    December 2024
  2. FALINI B, Tiacci E
    Hairy-Cell Leukemia. Reply.
    N Engl J Med. 2024;391:2388.
    PubMed    


  3. HERMEL DJ, Saven A
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2387-2388.
    PubMed    


  4. REINHOLD I, Cornely OA, Stemler J
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2386-2387.
    PubMed    


  5. ABRUZZESE E
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2276.
    PubMed    


  6. HOCHHAUS A, Cortes JE, Hughes TP
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2275-2276.
    PubMed    


  7. PUNWANI N
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2275.
    PubMed    


  8. GAMBACORTI-PASSERINI C, Piazza R
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2274-2275.
    PubMed    


  9. GUPTA S, Rau RE, Kairalla JA, Rabin KR, et al
    Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
    N Engl J Med. 2024 Dec 7. doi: 10.1056/NEJMoa2411680.
    PubMed     Abstract available


    November 2024
  10. RODDIE C, Sandhu KS, Tholouli E, Logan AC, et al
    Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
    N Engl J Med. 2024 Nov 27. doi: 10.1056/NEJMoa2406526.
    PubMed     Abstract available


    October 2024
  11. FALINI B, Tiacci E
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:1328-1341.
    PubMed    


    September 2024
  12. ABRUZZESE E
    CML 25 Years Later - Poised for Another Breakthrough?
    N Engl J Med. 2024;391:955-957.
    PubMed    


    August 2024
  13. HSU C, Konner JA, Gounder MM
    Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.
    N Engl J Med. 2024;391:770-772.
    PubMed    


    July 2024
  14. LITZOW MR, Sun Z, Mattison RJ, Paietta EM, et al
    Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    N Engl J Med. 2024;391:320-333.
    PubMed     Abstract available


    June 2024
  15. TIONG IS, Ritchie DS, Blombery P
    Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML.
    N Engl J Med. 2024;390:2323-2325.
    PubMed    


    May 2024
  16. HOCHHAUS A, Wang J, Kim DW, Kim DDH, et al
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024 May 31. doi: 10.1056/NEJMoa2400858.
    PubMed     Abstract available


  17. MUNIR T, Hillmen P
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply.
    N Engl J Med. 2024;390:1634-1635.
    PubMed    


  18. WANG WD, Gale RP, Liang Y
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    N Engl J Med. 2024;390:1633-1634.
    PubMed    


  19. WINKLER C
    Acute Promyelocytic Leukemia.
    N Engl J Med. 2024;390:e42.
    PubMed    


    April 2024
  20. BLAISE D
    CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
    N Engl J Med. 2024;390:1526-1527.
    PubMed    


  21. HU Y, Zhang M, Yang T, Mo Z, et al
    Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
    N Engl J Med. 2024;390:1467-1480.
    PubMed     Abstract available


    December 2023
  22. MUNIR T, Cairns DA, Bloor A, Allsup D, et al
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    N Engl J Med. 2023 Dec 10. doi: 10.1056/NEJMoa2310063.
    PubMed     Abstract available


    July 2023
  23. KATER AP, Eichhorst B
    Inhibiting BTK in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;389:83-86.
    PubMed    


  24. MATO AR, Woyach JA, Brown JR, Ghia P, et al
    Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;389:33-44.
    PubMed     Abstract available


    June 2023
  25. CHIESA R, Georgiadis C, Syed F, Zhan H, et al
    Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
    N Engl J Med. 2023 Jun 14. doi: 10.1056/NEJMoa2300709.
    PubMed     Abstract available


    May 2023
  26. FORCONI F, Ashton-Key M, Meakin N
    BCL2 Inhibition in Refractory Hairy-Cell Leukemia.
    N Engl J Med. 2023;388:2010-2012.
    PubMed    


  27. WOYACH JA, Byrd JC
    Time-Limited Initial Therapy for Young, Fit Patients with CLL.
    N Engl J Med. 2023;388:1812-1813.
    PubMed    


  28. EICHHORST B, Niemann CU, Kater AP, Furstenau M, et al
    First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;388:1739-1754.
    PubMed     Abstract available


  29. BROWN JR, Cohen A, Shadman M
    Zanubrutinib in Chronic Lymphocytic Leukemia. Reply.
    N Engl J Med. 2023;388:1720-1721.
    PubMed    


  30. LIANG Y, Gale RP
    Zanubrutinib in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;388:1720.
    PubMed    


  31. BYRD JC, Rothbaum W
    Zanubrutinib in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2023;388:1719-1720.
    PubMed    


    April 2023
  32. VAN DER SLUIS IM, de Lorenzo P, Kotecha RS, Attarbaschi A, et al
    Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    N Engl J Med. 2023;388:1572-1581.
    PubMed     Abstract available


    March 2023
  33. TIACCI E, De Carolis L, Santi A, Falini B, et al
    Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.
    N Engl J Med. 2023;388:952-954.
    PubMed    


    December 2022
  34. BROWN JR, Eichhorst B, Hillmen P, Jurczak W, et al
    Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    N Engl J Med. 2022 Dec 13. doi: 10.1056/NEJMoa2211582.
    PubMed     Abstract available


    June 2022
  35. MONTESINOS P, de Botton S, Dohner H
    Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
    N Engl J Med. 2022;386:2536-2537.
    PubMed    


  36. GOODMAN AM, Mohyuddin GR, Prasad V
    Ivosidenib and Azacitidine in IDH1-Mutated AML.
    N Engl J Med. 2022;386:2536.
    PubMed    


  37. GIL-SIERRA MD, Briceno-Casado MP, Sierra-Sanchez JF
    Ivosidenib and Azacitidine in IDH1-Mutated AML.
    N Engl J Med. 2022;386:2535-2536.
    PubMed    


  38. FOA R, Chiaretti S
    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    N Engl J Med. 2022;386:2399-2411.
    PubMed    


    May 2022
  39. RODRIGUES GR, Mendonca TM
    Retinal Hemorrhages in Leukemia.
    N Engl J Med. 2022;386:e50.
    PubMed    


    April 2022
  40. MONTESINOS P, Recher C, Vives S, Zarzycka E, et al
    Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
    N Engl J Med. 2022;386:1519-1531.
    PubMed     Abstract available


    February 2022
  41. WANG E, Mi X, Thompson MC, Montoya S, et al
    Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
    N Engl J Med. 2022;386:735-743.
    PubMed     Abstract available


    January 2022
  42. ROGERS E, Cusnir M
    Gingival Infiltration in Acute Monocytic Leukemia.
    N Engl J Med. 2022;386:79.
    PubMed    


    December 2021
  43. GOYAL S, Tisdale J, Schmidt M, Kanter J, et al
    Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
    N Engl J Med. 2021 Dec 12. doi: 10.1056/NEJMoa2109167.
    PubMed     Abstract available


    October 2021
  44. WOO SB, Wu MY, Treister NS, Amrein PC, et al
    Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers.
    N Engl J Med. 2021;385:1700-1710.
    PubMed    


    September 2021
  45. BARRY D, Schmieder A
    Leukemia Cutis.
    N Engl J Med. 2021;385:1316.
    PubMed    


    August 2021
  46. BRUNNER AM, Newcomb RA, Chen YB, Crabbe AM, et al
    Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia.
    N Engl J Med. 2021;385:834-843.
    PubMed    


  47. BEATTY CJ, Ghareeb ER
    Neutrophilic Eccrine Hidradenitis.
    N Engl J Med. 2021;385:e19.
    PubMed    


    May 2021
  48. MARKEWITZ RDH, Dargvainiene J
    Mitotic and Apoptotic Figures on a Peripheral-Blood Smear.
    N Engl J Med. 2021;384:1942.
    PubMed    


  49. TIACCI E, De Carolis L, Simonetti E, Capponi M, et al
    Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
    N Engl J Med. 2021;384:1810-1823.
    PubMed     Abstract available


  50. MEJIA BURITICA L, Karduss Urueta AJ
    Pulmonary Mucormycosis.
    N Engl J Med. 2021;384:e69.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.